Completed PHASE2 INTERVENTIONAL 1-arm NCT05605301

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

Sponsor: Epilepsy Foundation

Interventions Oral 2-Deoxy-D-Glucose (2DG)

Updated 4 times since 2022 Last updated: Feb 5, 2024 Started: Sep 2, 2022 Primary completion: Feb 5, 2024 Completion: Feb 5, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05605301, this PHASE2 trial focuses on Epilepsy; Seizure and remains completed. Sponsored by Epilepsy Foundation, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Dec 2022 — Mar 2024 [monthly]

Recruiting PHASE2

First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Epilepsy Foundation
University of Virginia
University of Wisconsin, Madison

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States